Biomarkers for immune checkpoint inhibitors in colorectal cancer: recent advances and future perspectives

Cancer Biol Med. 2023 Sep 14;20(9):633-639. doi: 10.20892/j.issn.2095-3941.2023.0201.

Authors

Changjiang Yang¹, Long Zhao¹, Yilin Lin¹, Shan Wang¹, Yingjiang Ye¹, Zhanlong Shen¹

Affiliation

¹ Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, Beijing 100044, China.

PMID: 37712582
PMCID: PMC10546092
DOI: 10.20892/j.issn.2095-3941.2023.0201

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Colorectal Neoplasms* / drug therapy
Humans
Immune Checkpoint Inhibitors* / pharmacology
Immune Checkpoint Inhibitors* / therapeutic use
Immunotherapy

Substances

Immune Checkpoint Inhibitors
Biomarkers

Grants and funding

This work was supported by the National Natural Science Foundation of China (Grant No. 82272841).